[Results of a post-marketing surveillance of meropenem for children]

Area of Science:

• Pediatric pharmacology
• Infectious disease management
• Post-marketing drug surveillance

Background:

• Meropenem is a broad-spectrum antibiotic used for serious bacterial infections.
• Post-marketing surveillance is crucial for evaluating drug safety and efficacy in real-world settings.

Purpose of the Study:

• To assess the safety and efficacy of meropenem in a pediatric population.
• To identify adverse drug reactions (ADRs) associated with meropenem use in children.

Main Methods:

• Post-marketing surveillance study conducted from May 2004 to September 2006.
• Analysis of safety data from 1210 pediatric cases.
• Evaluation of efficacy data from 1004 pediatric cases.

Main Results:

• The incidence of ADRs was 14.3% (173 cases), with common reactions including abnormal hepatic function, increased alanine aminotransferase, and increased aspartate aminotransferase.
• Efficacy was observed in 88.6% (890 cases) of the treated children.
• ADR profile was consistent with findings from prior clinical studies.

Conclusions:

• Meropenem demonstrated a favorable efficacy rate in pediatric patients.
• The safety profile, characterized by mild hepatic enzyme elevations, was acceptable and consistent with existing data.
• Post-marketing surveillance confirmed the therapeutic value of meropenem in pediatric practice.